1
|
Grob NM, Remarcik C, Rössler SL, Wong JYK, Wang JCK, Tao J, Smith CL, Loas A, Buchwald SL, Eaton DL, López MP, Pentelute BL. Electrophile Scanning Reveals Reactivity Hotspots for the Design of Covalent Peptide Binders. ACS Chem Biol 2024; 19:101-109. [PMID: 38069818 DOI: 10.1021/acschembio.3c00538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2024]
Abstract
Protein-protein interactions (PPIs) are intriguing targets in drug discovery and development. Peptides are well suited to target PPIs, which typically present with large surface areas lacking distinct features and deep binding pockets. To improve binding interactions with these topologies and advance the development of PPI-focused therapeutics, potential ligands can be equipped with electrophilic groups to enable binding through covalent mechanisms of action. We report a strategy termed electrophile scanning to identify reactivity hotspots in a known peptide ligand and demonstrate its application in a model PPI. Cysteine mutants of a known ligand are used to install protein-reactive modifiers via a palladium oxidative addition complex (Pd-OAC). Reactivity hotspots are revealed by cross-linking reactions with the target protein under physiological conditions. In a model PPI with the 9-mer peptide antigen VL9 and major histocompatibility complex (MHC) class I protein HLA-E, we identify two reactivity hotspots that afford up to 87% conversion to the protein-peptide conjugate within 4 h. The reactions are specific to the target protein in vitro and dependent on the peptide sequence. Moreover, the cross-linked peptide successfully inhibits molecular recognition of HLA-E by CD94-NKG2A possibly due to structural changes enacted at the PPI interface. The results illustrate the potential application of electrophile scanning as a tool for rapid discovery and development of covalent peptide binders.
Collapse
Affiliation(s)
- Nathalie M Grob
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - Clint Remarcik
- Calico Life Sciences LLC, San Francisco, California 94080, United States of America
| | - Simon L Rössler
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - Jeffrey Y K Wong
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - John C K Wang
- Calico Life Sciences LLC, San Francisco, California 94080, United States of America
| | - Jason Tao
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - Corey L Smith
- AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States of America
| | - Andrei Loas
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - Stephen L Buchwald
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| | - Dan L Eaton
- Calico Life Sciences LLC, San Francisco, California 94080, United States of America
| | | | - Bradley L Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States of America
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States of America
- Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States of America
| |
Collapse
|
2
|
Ye X, Zhang P, Tao J, Wang JCK, Mafi A, Grob NM, Quartararo AJ, Baddock HT, Chan LJG, McAllister FE, Foe I, Loas A, Eaton DL, Hao Q, Nile AH, Pentelute BL. Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6. Chem Sci 2023; 14:12484-12497. [PMID: 38020382 PMCID: PMC10646941 DOI: 10.1039/d3sc02782a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 08/22/2023] [Indexed: 12/01/2023] Open
Abstract
Human papillomavirus (HPV) infections account for nearly all cervical cancer cases, which is the fourth most common cancer in women worldwide. High-risk variants, including HPV16, drive tumorigenesis in part by promoting the degradation of the tumor suppressor p53. This degradation is mediated by the HPV early protein 6 (E6), which recruits the E3 ubiquitin ligase E6AP and redirects its activity towards ubiquitinating p53. Targeting the protein interaction interface between HPV E6 and E6AP is a promising modality to mitigate HPV-mediated degradation of p53. In this study, we designed a covalent peptide inhibitor, termed reactide, that mimics the E6AP LXXLL binding motif by selectively targeting cysteine 58 in HPV16 E6 with quantitative conversion. This reactide provides a starting point in the development of covalent peptidomimetic inhibitors for intervention against HPV-driven cancers.
Collapse
Affiliation(s)
- Xiyun Ye
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Peiyuan Zhang
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Jason Tao
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - John C K Wang
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Amirhossein Mafi
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Nathalie M Grob
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Anthony J Quartararo
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Hannah T Baddock
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Leanne J G Chan
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Fiona E McAllister
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Ian Foe
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Andrei Loas
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
| | - Dan L Eaton
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Qi Hao
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Aaron H Nile
- Calico Life Sciences LLC 1170 Veterans Boulevard South San Francisco CA 94080 USA
| | - Bradley L Pentelute
- Department of Chemistry, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology 500 Main Street Cambridge MA 02142 USA
- Center for Environmental Health Sciences, Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02139 USA
- Broad Institute of MIT and Harvard 415 Main Street Cambridge MA 02142 USA
| |
Collapse
|
3
|
Rössler SL, Grob NM, Buchwald SL, Pentelute BL. Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis. Science 2023; 379:939-945. [PMID: 36862767 PMCID: PMC10064805 DOI: 10.1126/science.adf1354] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Encoding small-molecule information in DNA has been leveraged to accelerate the discovery of ligands for therapeutic targets such as proteins. However, oligonucleotide-based encoding is hampered by inherent limitations of information stability and density. In this study, we establish abiotic peptides for next-generation information storage and apply them for the encoding of diverse small-molecule synthesis. The chemical stability of the peptide-based tag allows the use of palladium-mediated reactions to efficiently synthesize peptide-encoded libraries (PELs) with broad chemical diversity and high purity. We demonstrate the successful de novo discovery of small-molecule protein ligands from PELs by affinity selection against carbonic anhydrase IX and the oncogenic protein targets BRD4(1) and MDM2. Collectively, this work establishes abiotic peptides as carriers of information for the encoding of small-molecule synthesis, leveraged herein for the discovery of protein ligands.
Collapse
Affiliation(s)
- Simon L Rössler
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Nathalie M Grob
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Stephen L Buchwald
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Bradley L Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| |
Collapse
|
4
|
Vrettos EI, Valverde IE, Mascarin A, Pallier PN, Cerofolini L, Fragai M, Parigi G, Hirmiz B, Bekas N, Grob NM, Stylos EΚ, Shaye H, Del Borgo M, Aguilar M, Magnani F, Syed N, Crook T, Waqif E, Ghazaly E, Cherezov V, Widdop RE, Luchinat C, Michael‐Titus AT, Mindt TL, Tzakos AG. Cover Feature: Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity (Chem. Eur. J. 47/2020). Chemistry 2020. [DOI: 10.1002/chem.202003569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - Ibai E. Valverde
- Division of Radiopharmaceutical Chemistry University of Basel Hospital Petersgraben 4 4031 Basel Switzerland
- Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR 6302 CNRS Université de Bourgogne Franche-Comté 9 Avenue Alain Savary 21000 Dijon France
| | - Alba Mascarin
- Division of Radiopharmaceutical Chemistry University of Basel Hospital Petersgraben 4 4031 Basel Switzerland
| | - Patrick N. Pallier
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry Queen Mary, University of London 4 Newark Street, Whitechapel London E1 2AT UK
| | - Linda Cerofolini
- Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP) University of Florence Sesto Fiorentino 50019 Italy
| | - Marco Fragai
- Centre for Magnetic Resonance CERM University of Florence Sesto Fiorentino 50019 Italy
- Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP) University of Florence Sesto Fiorentino 50019 Italy
| | - Giacomo Parigi
- Centre for Magnetic Resonance CERM University of Florence Sesto Fiorentino 50019 Italy
- Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP) University of Florence Sesto Fiorentino 50019 Italy
| | - Baydaa Hirmiz
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology Monash University Clayton VIC 3800 Australia
| | - Nick Bekas
- Department of Chemistry University of Ioannina Ioannina 45110 Greece
| | - Nathalie M. Grob
- Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zürich Switzerland
| | | | - Hamidreza Shaye
- Bridge Institute Department of Chemistry University of Southern California. Los Angeles CA 90089 USA
| | - Mark Del Borgo
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology Monash University Clayton VIC 3800 Australia
| | - Marie‐Isabel Aguilar
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology Monash University Clayton VIC 3800 Australia
| | - Francesca Magnani
- Department of Biology and Biotechnology “Lazzaro Spallanzani” University of Pavia Pavia Italy
| | - Nelofer Syed
- John Fulcher Neuro-oncology Laboratory Division of Brain Sciences Faculty of Medicine Imperial College London London W6 8RP UK
| | - Timothy Crook
- Leaders in Oncology Care 95 Harley Street London W1G 6AF UK
| | - Emal Waqif
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry Queen Mary, University of London 4 Newark Street, Whitechapel London E1 2AT UK
| | - Essam Ghazaly
- Centre for Haemato-Oncology Barts Cancer Institute Queen Mary University of London London UK
| | - Vadim Cherezov
- Bridge Institute Department of Chemistry University of Southern California. Los Angeles CA 90089 USA
| | - Robert E. Widdop
- Monash Biomedicine Discovery Institute and Department of Pharmacology Monash University Clayton VIC 3800 Australia
| | - Claudio Luchinat
- Centre for Magnetic Resonance CERM University of Florence Sesto Fiorentino 50019 Italy
- Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP) University of Florence Sesto Fiorentino 50019 Italy
| | - Adina T. Michael‐Titus
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry Queen Mary, University of London 4 Newark Street, Whitechapel London E1 2AT UK
| | - Thomas L. Mindt
- Division of Radiopharmaceutical Chemistry University of Basel Hospital Petersgraben 4 4031 Basel Switzerland
- Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna Vienna Austria
- Ludwig Boltzmann Institute Applied Diagnostics General Hospital of Vienna Vienna Austria
- Institute of Inorganic Chemistry Faculty of Chemistry University of Vienna Vienna Austria
| | - Andreas G. Tzakos
- Department of Chemistry University of Ioannina Ioannina 45110 Greece
| |
Collapse
|
5
|
Vrettos EI, Valverde IE, Mascarin A, Pallier PN, Cerofolini L, Fragai M, Parigi G, Hirmiz B, Bekas N, Grob NM, Stylos EΚ, Shaye H, Del Borgo M, Aguilar MI, Magnani F, Syed N, Crook T, Waqif E, Ghazaly E, Cherezov V, Widdop RE, Luchinat C, Michael-Titus AT, Mindt TL, Tzakos AG. Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity. Chemistry 2020; 26:10690-10694. [PMID: 32691857 DOI: 10.1002/chem.202000924] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 05/03/2020] [Indexed: 12/13/2022]
Abstract
Mutating the side-chains of amino acids in a peptide ligand, with unnatural amino acids, aiming to mitigate its short half-life is an established approach. However, it is hypothesized that mutating specific backbone peptide bonds with bioisosters can be exploited not only to enhance the proteolytic stability of parent peptides, but also to tune its receptor subtype selectivity. Towards this end, four [Y]6 -Angiotensin II analogues are synthesized where amide bonds have been replaced by 1,4-disubstituted 1,2,3-triazole isosteres in four different backbone locations. All the analogues possessed enhanced stability in human plasma in comparison with the parent peptide, whereas only two of them achieved enhanced AT2 R/AT1 R subtype selectivity. This diversification has been studied through 2D NMR spectroscopy and unveiled a putative more structured microenvironment for the two selective ligands accompanied with increased number of NOE cross-peaks. The most potent analogue, compound 2, has been explored regarding its neurotrophic potential and resulted in an enhanced neurite growth with respect to the established agent C21.
Collapse
Affiliation(s)
| | - Ibai E Valverde
- Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland.,Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR 6302 CNRS, Université de Bourgogne Franche-Comté, 9 Avenue Alain Savary, 21000, Dijon, France
| | - Alba Mascarin
- Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland
| | - Patrick N Pallier
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, 4 Newark Street, Whitechapel, London, E1 2AT, UK
| | - Linda Cerofolini
- Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP), University of Florence, Sesto Fiorentino, 50019, Italy
| | - Marco Fragai
- Centre for Magnetic Resonance, CERM, University of Florence, Sesto Fiorentino, 50019, Italy.,Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP), University of Florence, Sesto Fiorentino, 50019, Italy
| | - Giacomo Parigi
- Centre for Magnetic Resonance, CERM, University of Florence, Sesto Fiorentino, 50019, Italy.,Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP), University of Florence, Sesto Fiorentino, 50019, Italy
| | - Baydaa Hirmiz
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia
| | - Nick Bekas
- Department of Chemistry, University of Ioannina, Ioannina, 45110, Greece
| | - Nathalie M Grob
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zürich, Switzerland
| | - Evgenios Κ Stylos
- Department of Chemistry, University of Ioannina, Ioannina, 45110, Greece
| | - Hamidreza Shaye
- Bridge Institute, Department of Chemistry, University of Southern California., Los Angeles, CA, 90089, USA
| | - Mark Del Borgo
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia
| | - Marie-Isabel Aguilar
- Monash Biomedicine Discovery Institute and Department of Biochemistry, and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia
| | - Francesca Magnani
- Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy
| | - Nelofer Syed
- John Fulcher Neuro-oncology Laboratory, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, W6 8RP, UK
| | - Timothy Crook
- Leaders in Oncology Care, 95 Harley Street, London, W1G 6AF, UK
| | - Emal Waqif
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, 4 Newark Street, Whitechapel, London, E1 2AT, UK
| | - Essam Ghazaly
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Vadim Cherezov
- Bridge Institute, Department of Chemistry, University of Southern California., Los Angeles, CA, 90089, USA
| | - Robert E Widdop
- Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, VIC, 3800, Australia
| | - Claudio Luchinat
- Centre for Magnetic Resonance, CERM, University of Florence, Sesto Fiorentino, 50019, Italy.,Consorzio Interuniversitario Risonanze Magnetiche MetalloProteine, (CIRMMP), University of Florence, Sesto Fiorentino, 50019, Italy
| | - Adina T Michael-Titus
- Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, 4 Newark Street, Whitechapel, London, E1 2AT, UK
| | - Thomas L Mindt
- Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland.,Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Vienna, Austria.,Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Vienna, Austria.,Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
| | - Andreas G Tzakos
- Department of Chemistry, University of Ioannina, Ioannina, 45110, Greece
| |
Collapse
|
6
|
Abstract
The insertion of single 1,4-disubstituted 1,2,3-triazoles as metabolically stable bioisosteres of trans-amide bonds (triazole scan) was recently applied to the 177Lu-labeled tumor-targeting analog of minigastrin, [Nle15]MG11. The reported novel mono-triazolo-peptidomimetics of [Nle15]MG11 showed either improved resistance against enzymatic degradation or a significantly increased affinity toward the target receptor but never both. To enhance further the tumor-targeting properties of the minigastrin analogs, we studied conjugates with multiple amide-to-triazole substitutions for additive or synergistic effects. Promising candidates were identified by modification of two or three amide bonds, which yielded both improved stability and increased receptor affinity of the peptidomimetics in vitro. Biodistribution studies of radiolabeled multi-triazolo-peptidomimetics in mice bearing receptor-positive tumor xenografts revealed up to 4-fold increased tumor uptake in comparison to the all-amide reference compound [Nle15]MG11. In addition, we report here for the first time a linear peptidomimetic with three triazole insertions in its backbone and maintained biological activity.
Collapse
Affiliation(s)
- Nathalie M Grob
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zürich, Switzerland
| | - Sarah Schmid
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zürich, Switzerland
| | - Roger Schibli
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zürich, Switzerland.,Center for Radiopharmaceutical Sciences, Division of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - Martin Behe
- Center for Radiopharmaceutical Sciences, Division of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, 1090 Vienna, Austria.,Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.,Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria
| |
Collapse
|
7
|
Grob NM, Häussinger D, Deupi X, Schibli R, Behe M, Mindt TL. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting. J Med Chem 2020; 63:4484-4495. [PMID: 32302139 DOI: 10.1021/acs.jmedchem.9b01936] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
MG11 is a truncated analog of minigastrin, a peptide with high affinity and specificity toward the cholecystokinin-2 receptor (CCK2R), which is overexpressed by different tumors. Thus, radiolabeled MG11 derivatives have great potential for use in cancer diagnosis and therapy. A drawback of MG11 is its fast degradation by proteases, leading to moderate tumor uptake in vivo. We introduced 1,4-disubstituted 1,2,3-triazoles as metabolically stable bioisosteres to replace labile amide bonds of the peptide. The "triazole scan" yielded peptidomimetics with improved resistance to enzymatic degradation and/or enhanced affinity toward the CCK2R. Remarkably, our lead compound achieved a 10-fold increase in receptor affinity, resulting in a 2.6-fold improved tumor uptake in vivo. Modeling of the ligand-CCK2R complex suggests that an additional cation-π interaction of the aromatic triazole moiety with the Arg356 residue of the receptor is accountable for these observations. We show for the first time that the amide-to-triazole substitution strategy offers new opportunities in drug development that go beyond the metabolic stabilization of bioactive peptides.
Collapse
Affiliation(s)
- Nathalie M Grob
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zürich, Switzerland
| | - Daniel Häussinger
- Department of Chemistry, University of Basel, 4056 Basel, Switzerland
| | - Xavier Deupi
- Condensed Matter Theory Group, Laboratory for Scientific Computing and Modelling, Paul Scherrer Institute, 5232 Villigen, Switzerland.,Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - Roger Schibli
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zürich, Switzerland.,Center for Radiopharmaceutical Sciences, Division of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - Martin Behe
- Center for Radiopharmaceutical Sciences, Division of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, 1090 Vienna, Austria.,Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.,Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria
| |
Collapse
|
8
|
Grob NM, Behe M, Guggenberg E, Schibli R, Mindt TL. Corrigendum concerning “Methoxinine—An alternative stable amino acid substitute for oxidation‐sensitive methionine in radiolabelled peptide conjugates”. J Pept Sci 2020; 26:e3242. [DOI: 10.1002/psc.3242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
9
|
Grob NM, Behe M, von Guggenberg E, Schibli R, Mindt TL. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. J Pept Sci 2017; 23:38-44. [PMID: 28054429 DOI: 10.1002/psc.2948] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 11/18/2016] [Accepted: 11/21/2016] [Indexed: 01/29/2023]
Abstract
Radiolabelled peptides with high specificity and affinity towards receptors that are overexpressed by tumour cells are used in nuclear medicine for the diagnosis (imaging) and therapy of cancer. In some cases, the sequences of peptides under investigations contain methionine (Met), an amino acid prone to oxidation during radiolabelling procedures. The formation of oxidative side products can affect the purity of the final radiopharmaceutical product and/or impair its specificity and affinity towards the corresponding receptor. The replacement of Met with oxidation resistant amino acid analogues, for example, norleucine (Nle), can provide a solution. While this approach has been applied successfully to different radiolabelled peptides, a Met → Nle switch only preserves the length of the amino acid side chain important for hydrophobic interactions but not its hydrogen-bonding properties. We report here the use of methoxinine (Mox), a non-canonical amino acid that resembles more closely the electronic properties of Met in comparison to Nle. Specifically, we replaced Met15 by Mox15 and Nle15 in the binding sequence of a radiometal-labelled human gastrin derivative [d-Glu10 ]HG(10-17), named MG11 (d-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 ). A comparison of the physicochemical properties of 177 Lu-DOTA[X15 ]MG11 (X = Met, Nle, Mox) in vitro (cell internalization/externalization properties, receptor affinity (IC50 ), blood plasma stability and logD) showed that Mox indeed represents a suitable, oxidation-stable amino acid substitute of Met in radiolabelled peptide conjugates. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Nathalie M Grob
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog Weg 4, CH-8093, Zurich, Switzerland
| | - Martin Behe
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, CH-5232, Villigen, Switzerland
| | | | - Roger Schibli
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog Weg 4, CH-8093, Zurich, Switzerland.,Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, CH-5232, Villigen, Switzerland
| | - Thomas L Mindt
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog Weg 4, CH-8093, Zurich, Switzerland.,Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria
| |
Collapse
|
10
|
Abstract
Exhaled breath condensate (EBC) is a potential rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. EBC has been studied in a variety of diseases including allergic rhinitis, asthma, chronic obstructive lung disease, cystic fibrosis, lung cancer, and obstructive sleep apnea syndrome. Although numerous biomarkers have been discovered and studied in EBC, the methods of collection and biomarker detection have not been fully standardized. While leaving standardization methods up to individual labs for the present time is optimal for the continued discovery of new biomarkers in EBC, this decreases the reproducibility and generalizability of the findings. In this review we will discuss specific biomarkers studied in specific diseases as well as some of the related technical issues including collection, processing and analysis.
Collapse
Affiliation(s)
- N M Grob
- Department of Pulmonary, Allergy, and Critical Care Medicine/Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Pathobiology/Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. Case Western Reserve University, School of Medicine, Cleveland, OH, USA
| | | | | |
Collapse
|